{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:15:31Z","timestamp":1785885331975,"version":"3.56.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["208378\/Z\/17\/Z"],"award-info":[{"award-number":["208378\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently in the elimination phase in the Indian subcontinent (ISC) and being targeted for elimination by 2030 in East Africa (EA).\u00a0Maintaining the necessary financial and political commitments to achieve and sustain the current\u00a0elimination\u00a0efforts remains challenging. As with other NTDs, VL research is constrained by limited funding, and drug development has relied largely on partnerships between not-for-profit organisations and the pharmaceutical industry. Conducting robust clinical studies remains difficult, and therapeutic innovations have been limited. However, re-use of existing data offers an untapped opportunity to generate new evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We describe the process of developing a global VL research agenda and the establishment of an individual participant data (IPD) platform at the Infectious Diseases Data Observatory (IDDO). Key steps included a systematic scoping review of VL clinical trials, consultations with the Scientific Advisory Committee, expert and public reviews, and implementation of an equitable governance framework to harmonise and share IPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The VL research agenda, finalised in 2019, identified priority methodological and clinical questions suited to IPD analyses. The IDDO VL platform currently hosts harmonised data from nearly 15,000 patients across more than 50 studies (VL and post-kala-azar dermal leishmaniasis, PKDL). The platform is an inclusive resource guided by an equitable governance framework and provides a critical asset to support new evidence generation and can serve as a historical data to support accelerated\u00a0drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The development of a global VL research agenda has provided an inventory of priority research questions of public health importance. A shared IPD platform aligned with this agenda was developed to complement ongoing global efforts. In addition, such a platform can accelerate secondary evidence generation, support methodological innovation and inform future trial designs and policy. Sustained collaboration and investment are needed to maximise the scientific and public health value of data re-use in VL and PKDL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-025-07121-2","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:53:15Z","timestamp":1764687195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities"],"prefix":"10.1186","volume":"18","author":[{"given":"Sauman","family":"Singh-Phulgenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany J.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitali","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon L.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"7121_CR1","unstructured":"Infectious diseases data observatory. https:\/\/www.iddo.org\/. (Accessed 13 Aug 2024)"},{"key":"7121_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371","volume":"10","author":"WorldWide Antimalarial Resistance Network (WWARN) DP Study Group","year":"2013","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:1\u201317.","journal-title":"PLoS Med"},{"key":"7121_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002212","volume":"14","author":"RM Hoglund","year":"2017","unstructured":"Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, et\u00a0al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14:1\u201323.","journal-title":"PLoS Med"},{"key":"7121_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0140-6736(22)01881-5","volume":"401","author":"M Saito","year":"2023","unstructured":"Saito M, McGready R, Tinto H, Rouamba T, Mosha D, Rulisa S, et\u00a0al. Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis. Lancet. 2023;401:118\u201330.","journal-title":"Lancet"},{"key":"7121_CR5","unstructured":"Infectious Diseases Data Observatory. IDDO\u2019s governance structure. www.iddo.org. 2024. https:\/\/www.iddo.org\/governance. (Accessed 21 Jan 2024)"},{"key":"7121_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/wellcomeopenres.12259.1","volume":"2","author":"E Pisani","year":"2017","unstructured":"Pisani E, Botchway S. Sharing individual patient and parasite-level data through the WorldWide Antimalarial Resistance Network platform: a qualitative case study. Wellcome Open Res. 2017;2:63.","journal-title":"Wellcome Open Res"},{"key":"7121_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004784","volume":"10","author":"AM Jul\u00e9","year":"2016","unstructured":"Jul\u00e9 AM, Vaillant M, Lang TA, Gu\u00e9rin PJ, Olliaro PL. The schistosomiasis clinical trials landscape: a systematic review of antischistosomal treatment efficacy studies and a case for sharing individual participant-level data (IPD). PLoS Negl Trop Dis. 2016;10:1\u201317.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0005781","volume":"11","author":"JT Bush","year":"2017","unstructured":"Bush JT, Wasunna M, Alves F, Alvar J, Olliaro PL, Otieno M, et\u00a0al. Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: a first step to assess the feasibility of establishing an individual patient data sharing platform. PLoS Negl Trop Dis. 2017;11:1\u201316.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0006053","volume":"11","author":"JB Halder","year":"2017","unstructured":"Halder JB, Benton J, Jul\u00e9 AM, Gu\u00e9rin PJ, Olliaro PL, Bas\u00e1\u00f1ez MG, et\u00a0al. Systematic review of studies generating individual participant data on the efficacy of drugs for treating soil-transmitted helminthiases and the case for data-sharing. PLoS Negl Trop Dis. 2017;11:1\u201320.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0009697","volume":"15","author":"BJ Maguire","year":"2021","unstructured":"Maguire BJ, Dahal P, Rashan S, Ngu R, Boon A, Forsyth C, et\u00a0al. The Chagas disease study landscape: a systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform. PLoS Negl Trop Dis. 2021;15:1\u201320.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0009858","volume":"15","author":"K Saraswati","year":"2021","unstructured":"Saraswati K, Maguire BJ, McLean ARD, Singh-Phulgenda S, Ngu RC, Newton PN, et\u00a0al. Systematic review of the scrub typhus treatment landscape: assessing the feasibility of an individual participant-level data (IPD) platform. PLoS Negl Trop Dis. 2021;15:1\u201322.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0011635","volume":"18","author":"S Singh-Phulgenda","year":"2024","unstructured":"Singh-Phulgenda S, Kumar R, Dahal P, Munir A, Rashan S, Chhajed R, et\u00a0al. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: a systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform. PLoS Negl Trop Dis. 2024;18:1\u201327.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR13","unstructured":"World Health Organization. Leishmaniasis. 2023 (Accessed 2023 Apr 5). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis"},{"key":"7121_CR14","first-page":"364","volume":"22","author":"S Rijal","year":"2019","unstructured":"Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ. 2019;22:364.","journal-title":"BMJ"},{"key":"7121_CR15","unstructured":"World Health Organization. Bangladesh achieves historic milestone by eliminating kala-azar as a public health problem. World Heal. Organ. 2023. https:\/\/www.who.int\/news\/item\/31-10-2023-bangladesh-achieves-historic-milestone-by-eliminating-kala-azar-as-a-public-health-problem. (Accessed 9 May 2025)"},{"key":"7121_CR16","unstructured":"National Center for Vector Borne Diseases Control (NCVBDC), Ministry of Health & Family Welfare G of I. Kala-Azar Situation in India. https:\/\/ncvbdc.mohfw.gov.in. 2025. https:\/\/ncvbdc.mohfw.gov.in\/index4.php?lang=1&level=0&linkid=467&lid=3750. (Accessed 9 May 2025)"},{"key":"7121_CR17","unstructured":"Kala-Azar elimination program. Dep. Heal. Serv. Epidemiol. Dis. Control Div. Gov. Nepal. 2025. https:\/\/edcd.gov.np\/section\/kala-azar-elimination-program. (Accessed 30 Jun 2025)"},{"key":"7121_CR18","unstructured":"World Health Organization. Strategic framework for the elimination of visceral leishmaniasis as a public health problem in Eastern Africa 2023\u20132030. World Heal. Organ. Geneva, Switzerland; 2024."},{"key":"7121_CR19","unstructured":"World Health Organization. Statement on miltefosine - Potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL). 10 February 2022. who.int. 2022. https:\/\/www.who.int\/news\/item\/10-02-2022-statement-on-miltefosine---potential-ocular-disorders-in-patients-treated-with-miltefosine-for-post-kala-azar-dermal-leishmaniasis-(pkdl). (Accessed 5 Sept 2023)"},{"key":"7121_CR20","unstructured":"World Health Organization. Advisory Committee on Safety of Medicinal Products (ACSoMP): measures to minimize the risk of ocular adverse events with miltefosine. www.who.int. 2023. https:\/\/www.who.int\/news\/item\/12-04-2023-acsomp-miltefosine. (Accessed 5 Sept 2023)"},{"key":"7121_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009650","volume":"15","author":"P Dahal","year":"2021","unstructured":"Dahal P, Singh-Phulgenda S, Maguire BJ, Harriss E, Ritmeijer K, Alves F, et\u00a0al. Visceral leishmaniasis in pregnancy and vertical transmission: a systematic literature review on the therapeutic orphans. PLoS Negl Trop Dis. 2021;15:e0009650.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR22","first-page":"1","volume":"00","author":"P Dahal","year":"2024","unstructured":"Dahal P, Singh-Phulgenda S, Naylor C, Brack M, Chatterjee M, Alves F, et\u00a0al. Design, conduct, analysis, and reporting of therapeutic efficacy studies in visceral leishmaniasis: a systematic review of published reports, 2000\u20132021. Am J Trop Med Hyg. 2024;00:1\u201312.","journal-title":"Am J Trop Med Hyg"},{"key":"7121_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00048-18","volume":"31","author":"F Alves","year":"2018","unstructured":"Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et\u00a0al. Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018;31:1\u201330.","journal-title":"Clin Microbiol Rev"},{"key":"7121_CR24","unstructured":"Infectious Diseases Data Observatory. Visceral leishmaniasis data inventory. www.iddo.org. 2024. https:\/\/www.iddo.org\/document\/visceral-leishmaniasis-data-inventory. (Accessed 21 Jan 2024)"},{"key":"7121_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1473-3099(02)00347-X","volume":"2","author":"PJ Guerin","year":"2002","unstructured":"Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et\u00a0al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2:494\u2013501.","journal-title":"Lancet Infect Dis"},{"key":"7121_CR26","unstructured":"Infectious Diseases Data Observatory. Visceral leishmaniasis research agenda. 2019. https:\/\/www.iddo.org\/sites\/default\/files\/publication\/2019-09\/VL Research Agenda_Version 1.0_15JUL19.pdf. (Accessed 13 Aug 2024)"},{"key":"7121_CR27","unstructured":"Infectious Diseases Data Observatory. Scientific Advisory Committee: Infectious Diseases Data Observatory Visceral Leishmaniasis Research Theme. www.iddo.org. 2024. https:\/\/www.iddo.org\/vl\/governance\/scientific-advisory-committee. (Accessed 6 Aug 2024)"},{"key":"7121_CR28","unstructured":"Dahal P, Singh-Phulgenda S, Buck G, Stepniewska K, Guerin PJ. Data retrieval for individual participant data meta-analysis in the context of a neglected tropical disease: challenges and lessons from the Infectious Diseases Data Observatory Visceral Leishmaniasis data platform. In Prep. 2024."},{"key":"7121_CR29","unstructured":"Infectious Diseases Data Observatory. IDDO Data Access Committee. www.iddo.org. https:\/\/www.iddo.org\/governance\/data-access-committee. (Accessed 6 Aug 2024)"},{"key":"7121_CR30","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2666-5247(20)30166-X","volume":"2","author":"OP Singh","year":"2021","unstructured":"Singh OP, Tiwary P, Kushwaha AK, Singh SK, Singh DK, Lawyer P, et\u00a0al. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. The Lancet Microbe 2021;2:e23-31.","journal-title":"The Lancet Microbe Elsevier Ltd"},{"key":"7121_CR31","volume":"22","author":"R Chhajed","year":"2024","unstructured":"Chhajed R, Dahal P, Singh-Phulgenda S, Brack M, Naylor C, Sundar S, Alves F, Stepniewska K, Guerin PJ. Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic review. Lancet Reg Health Southeast Asia. 2023 Dec 6; 22:100317","journal-title":"Lancet Reg Health"},{"key":"7121_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0010696","volume":"16","author":"G Naylor-leyland","year":"2022","unstructured":"Naylor-leyland G, Collin SM, Gatluak F, Id MDB, Alves F, Mullahzada AW, et\u00a0al. The increasing incidence of visceral leishmaniasis relapse in South Sudan: a retrospective analysis of field patient data from 2001\u20132018. PLoS Negl Trop Dis. 2022;16:1\u201314.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S0031182017002116","volume":"145","author":"S Sundar","year":"2018","unstructured":"Sundar S, Singh A. Chemotherapeutics of visceral leishmaniasis: present and future developments. Parasitology. 2018;145:481\u20139.","journal-title":"Parasitology"},{"key":"7121_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"SL Croft","year":"2006","unstructured":"Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111\u201326.","journal-title":"Clin Microbiol Rev"},{"key":"7121_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0974-777X.62886","volume":"2","author":"S Sundar","year":"2010","unstructured":"Sundar S, Jaya J. Liposomal amphotericin B and leishmaniasis: dose and response. J Glob Infect Dis. 2010;2:159.","journal-title":"J Glob Infect Dis"},{"key":"7121_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0003820","volume":"9","author":"L Gonzalez-Fajardo","year":"2015","unstructured":"Gonzalez-Fajardo L, Fern\u00e1ndez OL, McMahon-Pratt D, Saravia NG. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. PLoS Negl Trop Dis. 2015;9:1\u201319.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, L\u00f3pez-V\u00e9lez R, Garc\u00eda-Hern\u00e1ndez R, et\u00a0al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis. 2017;11:1\u201324.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000705","author":"S Gorski","year":"2010","unstructured":"Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, Mueller M, et\u00a0al. Visceral leishmaniasis relapse in Southern Sudan (1999\u20132007): a retrospective study of risk factors and trends. PLoS Negl Trop Dis. 2010.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0001153","volume":"5","author":"GF Cota","year":"2011","unstructured":"Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis. 2011;5:1\u20138.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR40","first-page":"44","volume":"8","author":"S Burza","year":"2014","unstructured":"Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, et\u00a0al. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) in Bihar. India PLoS Negl Trop Dis. 2014;8:44.","journal-title":"India PLoS Negl Trop Dis"},{"key":"7121_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100220","author":"B Ostyn","year":"2014","unstructured":"Ostyn B, Hasker E, Dorlo TPC, Rijal S, Sundar S, Dujardin JC, et\u00a0al. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PLoS One. 2014.","journal-title":"PLoS ONE"},{"key":"7121_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4269\/ajtmh.19-0179","volume":"101","author":"S Sundar","year":"2019","unstructured":"Sundar S, Singh A, Agrawal N, Chakravarty J. Effectiveness of single-dose liposomal amphotericin B in visceral leishmaniasis in Bihar. Am J Trop Med Hyg. 2019;101:795\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"7121_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100487","author":"Y Takele","year":"2022","unstructured":"Takele Y, Mulaw T, Adem E, Shaw CJ, Franssen SU, Womersley R, et\u00a0al. Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. Cell Rep Med. 2022.","journal-title":"Cell Rep Med"},{"key":"7121_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074679","volume":"13","author":"R Kumar","year":"2023","unstructured":"Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A, Naylor C, et\u00a0al. Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis. BMJ Open. 2023;13:e074679.","journal-title":"BMJ Open"},{"key":"7121_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075597","volume":"13","author":"J Wilson","year":"2023","unstructured":"Wilson J, Chowdhury F, Hassan S, Harriss EK, Alves F, Dahal P, et\u00a0al. Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review. BMJ Open. 2023;13:e075597.","journal-title":"BMJ Open"},{"key":"7121_CR46","unstructured":"Infectious Diseases Data Observatory. Development and validation of a prognostic model for visceral leishmaniasis relapse. www.iddo.org. 2024. https:\/\/www.iddo.org\/development-and-validation-prognostic-model-visceral-leishmaniasis-relapse. (Accessed 24 Nov 2024)"},{"key":"7121_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1017\/S0031182016002031","volume":"145","author":"S Hendrickx","year":"2018","unstructured":"Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L. Evaluating drug resistance in visceral leishmaniasis: the challenges. Parasitology. 2018;145:453\u201363.","journal-title":"Parasitology"},{"key":"7121_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pt.2023.01.012","volume":"39","author":"MA Domagalska","year":"2023","unstructured":"Domagalska MA, Barrett MP, Dujardin JC. Drug resistance in Leishmania: does it really matter? Trends Parasitol. 2023;39:251\u20139.","journal-title":"Trends Parasitol"},{"key":"7121_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s004300100086","volume":"190","author":"A Bryceson","year":"2001","unstructured":"Bryceson A. Current issues in the treatment of visceral leishmaniasis. Med Microbiol Immunol. 2001;190:81\u20134.","journal-title":"Med Microbiol Immunol"},{"key":"7121_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/infdis\/jiu039","volume":"210","author":"TPC Dorlo","year":"2014","unstructured":"Dorlo TPC, Rijal S, Ostyn B, De Vries PJ, Singh R, Bhattarai N, et\u00a0al. Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis. 2014;210:146\u201353.","journal-title":"J Infect Dis"},{"key":"7121_CR51","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1093\/jac\/dkx283","volume":"72","author":"TPC Dorlo","year":"2017","unstructured":"Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, et\u00a0al. Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic\/pharmacodynamic study. J Antimicrob Chemother. 2017;72:3131\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"7121_CR52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/trstmh\/trw031","volume":"110","author":"M Wasunna","year":"2016","unstructured":"Wasunna M, Musa A, Hailu A, Khalil EAG, Olobo J, Juma R, et\u00a0al. The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2016;110:321\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7121_CR53","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/jac\/dks275","volume":"67","author":"TPC Dorlo","year":"2012","unstructured":"Dorlo TPC, Balasegaram M, Beijnen JH, de vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:2576\u201397.","journal-title":"J Antimicrob Chemother"},{"key":"7121_CR54","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/cid\/ciy747","volume":"68","author":"J Mbui","year":"2019","unstructured":"Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, et\u00a0al. Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II clinical trial. Clin Infect Dis. 2019;68:1530\u20138.","journal-title":"Clin Infect Dis"},{"key":"7121_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac643","volume":"76","author":"AM Musa","year":"2023","unstructured":"Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, et\u00a0al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: a randomized, controlled, multicountry trial. Clin Infect Dis. 2023;76:E1177\u201385.","journal-title":"Clin Infect Dis"},{"key":"7121_CR56","doi-asserted-by":"crossref","unstructured":"Boelaert M, Alves F, Sundar S. Leishmaniasis. Manson\u2019s Trop Dis fourth ed. 2023;4:646\u201368.","DOI":"10.1016\/B978-0-7020-7959-7.00053-1"},{"key":"7121_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0008221","volume":"14","author":"MR Gedda","year":"2020","unstructured":"Gedda MR, Singh B, Kumar D, Singh AK, Madhukar P, Upadhyay S, et\u00a0al. Post kala-azar dermal leishmaniasis: a threat to elimination program. PLoS Negl Trop Dis. 2020;14:1\u201325.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR58","first-page":"341","volume":"70","author":"M Addy","year":"1992","unstructured":"Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ. 1992;70:341\u20136.","journal-title":"Bull World Health Organ"},{"key":"7121_CR59","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/cid\/cix245","volume":"65","author":"R Molina","year":"2017","unstructured":"Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal Di, et\u00a0al. Infectivity of post-kala-azar dermal leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent. Clin Infect Dis. 2017;65:150\u20133.","journal-title":"Clin Infect Dis"},{"key":"7121_CR60","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/cid\/ciy891","volume":"69","author":"D Mondal","year":"2019","unstructured":"Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, et\u00a0al. Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies. Clin Infect Dis. 2019;69:251\u20138.","journal-title":"Clin Infect Dis"},{"key":"7121_CR61","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.pt.2019.06.007","volume":"35","author":"EA Le Rutte","year":"2019","unstructured":"Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-azar dermal leishmaniasis as a reservoir for visceral leishmaniasis transmission. Trends Parasitol. 2019;35:590\u20132.","journal-title":"Trends Parasitol"},{"key":"7121_CR62","first-page":"144","volume":"91","author":"C Thakur","year":"1990","unstructured":"Thakur C, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J Med Res. 1990;91:144\u20138.","journal-title":"Indian J Med Res"},{"key":"7121_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1236952","author":"A Kumar","year":"2023","unstructured":"Kumar A, Singh VK, Tiwari R, Madhukar P, Kumar S, Kumar R. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination. Front Immunol. 2023.","journal-title":"Front Immunol"},{"key":"7121_CR64","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1086\/381203","volume":"38","author":"S Collin","year":"2004","unstructured":"Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, et\u00a0al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in Southern Sudan. Clin Infect Dis. 2004;38:612\u20139.","journal-title":"Clin Infect Dis"},{"key":"7121_CR65","first-page":"1","volume":"14","author":"V Goyal","year":"2020","unstructured":"Goyal V, Das VNR, Singh SN, Singh RS, Pandey K, Verma N, et\u00a0al. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar. India PLoS Negl Trop Dis. 2020;14:1\u201312.","journal-title":"India PLoS Negl Trop Dis"},{"key":"7121_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0007653","volume":"13","author":"D Mondal","year":"2019","unstructured":"Mondal D, Kumar A, Sharma A, Ahmed MM, Hasnain MG, Alim A, et\u00a0al. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: a cohort study from Bangladesh. PLoS Negl Trop Dis. 2019;13:1\u201316.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR67","unstructured":"Chatterjee M, Roy S, Croft SL. Challenges in sustaining the elimination of visceral leishmaniasis in India. Int Health. 2025 Jun 18:ihaf063."},{"key":"7121_CR68","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.4103\/amsr.amsr_45_24","volume":"4","author":"P Dahal","year":"2025","unstructured":"Dahal P, Singh-Phulgenda S, Assefa DG, Guerin PJ. Addressing research questions in visceral leishmaniasis and post-kala-azar dermal leishmaniasis: potential of reusing data from the Infectious Diseases Data Observatory platform. Ann Med Sci Res. 2025;4:S24-34.","journal-title":"Ann Med Sci Res"},{"key":"7121_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009302","volume":"15","author":"S Singh-Phulgenda","year":"2021","unstructured":"Singh-Phulgenda S, Dahal P, Ngu R, Maguire BJ, Hawryszkiewycz A, Rashan S, et\u00a0al. Serious adverse events and mortality following treatment of visceral leishmaniasis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15:e0009302.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074841","volume":"12","author":"A Munir","year":"2023","unstructured":"Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA, Naylor C, et\u00a0al. Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis. BMJ Open. 2023;12:e074841.","journal-title":"BMJ Open"},{"key":"7121_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0006781","volume":"12","author":"S Maruf","year":"2018","unstructured":"Maruf S, Nath P, Islam MR, Aktar F, Anuwarul A, Mondal D, et\u00a0al. Corneal complications following post kala-azar dermal leishmaniasis treatment. PLoS Negl Trop Dis. 2018;12:1\u20139.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40249-018-0461-0","volume":"7","author":"MS Hossain","year":"2018","unstructured":"Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, et\u00a0al. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh\u2019s National Kala-Azar Elimination Programme. Infect Dis Poverty. 2018;7:1\u201313.","journal-title":"Infect Dis Poverty"},{"key":"7121_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0007173","volume":"13","author":"J Pijpers","year":"2019","unstructured":"Pijpers J, Den Boer ML, Essink DR, Ritmeijer K. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia \u2013 A review and meta-analysis. PLoS Negl Trop Dis. 2019;13:1\u201314.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317325","author":"R Kusumesh","year":"2020","unstructured":"Kusumesh R, Ambasta A, Arya LK, Mohan N, Sinha BP, Ravidas V. Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. Br J Ophthalmol. 2020.","journal-title":"Br J Ophthalmol"},{"key":"7121_CR75","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0049475519877317","volume":"50","author":"S Saurabh","year":"2020","unstructured":"Saurabh S, Mahabir M. Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India. Trop Doct. 2020;50:37\u201342.","journal-title":"Trop Doct"},{"key":"7121_CR76","first-page":"1","volume":"2020","author":"A Pradhan","year":"2020","unstructured":"Pradhan A, Tobgay T, Dorjee S, Wangdi T, Zhou G, Karunaweera ND. Atypical presentation of post-kala-azar dermal leishmaniasis in Bhutan. Case Rep Dermatol Med. 2020;2020:1\u20134.","journal-title":"Case Rep Dermatol Med"},{"key":"7121_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/0037-8682-0208-2020","volume":"54","author":"K Pandey","year":"2021","unstructured":"Pandey K, Pal B, Topno RK, Lal CS, Das VNR, Das P. Acute uveitis: a rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis. Rev Soc Bras Med Trop. 2021;54:1\u20133.","journal-title":"Rev Soc Bras Med Trop"},{"key":"7121_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofad231","volume":"10","author":"S Sundar","year":"2023","unstructured":"Sundar S, Singh J, Dinkar A, Agrawal N. Safety and effectiveness of miltefosine in post-kala-azar dermal leishmaniasis: an observational study. Open Forum Infect Dis. 2023;10:1\u20136.","journal-title":"Open Forum Infect Dis"},{"key":"7121_CR79","unstructured":"IMPAVIDO (miltefosine) package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204684s000lbl.pdf. (Accessed 25 Mar 2021)"},{"key":"7121_CR80","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","volume":"352","author":"S Sundar","year":"1998","unstructured":"Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et\u00a0al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352:1821\u20133.","journal-title":"Lancet"},{"key":"7121_CR81","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","volume":"341","author":"TK Jha","year":"1999","unstructured":"Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et\u00a0al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med. 1999;341:1795\u2013800.","journal-title":"N Engl J Med"},{"key":"7121_CR82","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1999.11813462","author":"S Sundar","year":"1999","unstructured":"Sundar S, Gupta L, Makharia M, Singh M, Voss A, Rosenkaimer F, et\u00a0al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol. 1999.","journal-title":"Ann Trop Med Parasitol"},{"key":"7121_CR83","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/318122","volume":"31","author":"S Sundar","year":"2000","unstructured":"Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, et\u00a0al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis. 2000;31:1110\u20133.","journal-title":"Clin Infect Dis"},{"key":"7121_CR84","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa021556","volume":"347","author":"S Sundar","year":"2002","unstructured":"Sundar S, Jha T, Thakur C, Engel J, Sindermann H, Fischer C, et\u00a0al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739\u201346.","journal-title":"N Engl J Med"},{"key":"7121_CR85","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/01.inf.0000066877.72624.cb","volume":"22","author":"S Sundar","year":"2003","unstructured":"Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J. 2003;22:434\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"7121_CR86","first-page":"1076","volume":"43","author":"UK Singh","year":"2006","unstructured":"Singh UK, Prasad R, Kumar R, Jaiswal BP. Miltefosine in children with visceral leishmaniasis. Indian Pediatr. 2006;43:1076\u201380.","journal-title":"Indian Pediatr"},{"key":"7121_CR87","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/BF02763048","volume":"73","author":"UK Singh","year":"2006","unstructured":"Singh UK, Prasad R, Mishra OP, Jayswal BP. Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study. Indian J Pediatr. 2006;73:1077\u201380.","journal-title":"Indian J Pediatr"},{"key":"7121_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/trstmh\/trae018","volume":"118","author":"P Dahal","year":"2024","unstructured":"Dahal P, Singh-Phulgenda S, Wilson J, Cota G, Ritmeijer K, Musa A, et\u00a0al. Blood transfusion in the care of patients with visceral leishmaniasis: a review of practices in therapeutic efficacy studies. Trans R Soc Trop Med Hyg. 2024;118:1\u201310.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7121_CR89","unstructured":"WHO. Regional strategic framework for elimination of kala-azar from the South-East Asia region (2005\u20132015). World Heal Organ. 2005;"},{"key":"7121_CR90","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182016002031","author":"S Hendrickx","year":"2016","unstructured":"Hendrickx S, Guerin P, Caljon G, Croft S, Maes L. Evaluating drug resistance in visceral leishmaniasis: the challenges. Parasitology. 2016.","journal-title":"Parasitology"},{"key":"7121_CR91","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1016\/S1473-3099(16)30140-2","volume":"16","author":"OP Singh","year":"2016","unstructured":"Singh OP, Hasker E, Boelaert M, Sundar S. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016;16:e304\u20139.","journal-title":"Lancet Infect Dis"},{"key":"7121_CR92","first-page":"62","volume":"12","author":"D Bora","year":"1999","unstructured":"Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India. 1999;12:62\u20138.","journal-title":"Natl Med J India"},{"key":"7121_CR93","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3201\/eid2003.130260","volume":"20","author":"AM Khan","year":"2014","unstructured":"Khan AM, Dutta P, Khan SA, Baruah SK, Raja D, Khound K, et\u00a0al. Kala-azar and post-kala-azar dermal leishmaniasis, Assam. India Emerg Infect Dis. 2014;20:487\u20139.","journal-title":"India. Emerg Infect Dis."},{"key":"7121_CR94","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4103\/0972-9062.383637","volume":"60","author":"E Martschew","year":"2023","unstructured":"Martschew E, Al-Aghbari AA, Joshi AB, Kroeger A, Paudel KP, Dahal G, et\u00a0al. Visceral leishmaniasis in new foci areas of Nepal: sources and extent of infection. J Vector Borne Dis. 2023;60:414\u201320.","journal-title":"J Vector Borne Dis"},{"key":"7121_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0035-9203(91)90293-8","volume":"85","author":"EE Zijlstra","year":"1991","unstructured":"Zijlstra EE, Ali MS, El-Hassan AM, El-Toum IA, Satti M, Ghalib HW, et\u00a0al. Kala-azar in displaced people from southern Sudan: epidemiological, clinical and therapeutic findings. Trans R Soc Trop Med Hyg. 1991;85:365\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7121_CR96","first-page":"98","volume":"1","author":"MH Sati","year":"1962","unstructured":"Sati MH. Early phases of an outbreak of kala-azar in the Southern Fung. Sudan Med J. 1962;1:98\u2013111.","journal-title":"Sudan Med J"},{"key":"7121_CR97","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et\u00a0al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873\u201382.","journal-title":"Nat Rev Microbiol"},{"key":"7121_CR98","unstructured":"DNDi. Our R & D portfolio for visceral leishmaniasis. 2025. https:\/\/dndi.org\/diseases\/visceral-leishmaniasis\/projects-achievements\/. (Accessed 16 Jul 2025)"},{"key":"7121_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011188","volume":"17","author":"C Boodman","year":"2023","unstructured":"Boodman C, van Griensven J, Gupta N, Diro E, Ritmeijer K. Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia. PLoS Negl Trop Dis. 2023;17:e0011188.","journal-title":"PLoS Negl Trop Dis"},{"key":"7121_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/wellcomeopenres.17739.1","volume":"7","author":"S Singh-Phulgenda","year":"2022","unstructured":"Singh-Phulgenda S, Rashan S, Harriss E, Prabin D, Naylor C, Brack M, et\u00a0al. Infectious diseases data observatory (IDDO) visceral leishmaniasis library of clinical therapeutic studies\u202f: a protocol for a living systematic review of clinical studies. Wellcome Open Res. 2022;7:1\u20136.","journal-title":"Wellcome Open Res."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-025-07121-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-025-07121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:02:24Z","timestamp":1764691344000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-025-07121-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7121"],"URL":"https:\/\/doi.org\/10.1186\/s13071-025-07121-2","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}